Clinical characteristics and outcome of 261 ALL patients according to gene methylation status
| Feature . | Nonmethylated,no. patients . | Methylated,no. patients . | P . |
|---|---|---|---|
| Total | 100 | 161 | |
| Age | NS | ||
| Younger than 15 y | 43 | 57 | |
| Older than 15 y | 35 | 65 | |
| Sex (M/F) | 60/40 | 61/39 | NS |
| WBC count | NS | ||
| Less than 50 × 109/L | 75 | 70 | |
| More than 50 × 109/L | 25 | 30 | |
| FAB classification | NS | ||
| L1 | 39 | 32 | |
| L2 | 49 | 57 | |
| L3 | 12 | 11 | |
| Blast lineage | NS | ||
| B cell | 91 | 89 | |
| T cell | 9 | 11 | |
| NCI risk groups | NS | ||
| Standard | 79 | 66 | |
| Poor | 21 | 34 | |
| PETHEMA risk groups | NS | ||
| Standard | 41 | 34 | |
| Poor | 59 | 66 | |
| Treatment | NS | ||
| PETHEMA 89 | 20 | 19 | |
| PETHEMA 93 | 80 | 81 | |
| BMT | 19 | 16 | NS |
| Best response | |||
| CR | 87 | 93 | NS |
| Cytogenetic/molecular abnormalities | NS | ||
| BCR-ABL | 17 | 14 | |
| t(1;19) | 4 | 2 | |
| 11q23 | 3 | 3 | |
| c-myc | 6 | 8 | |
| 7q35-14q11 | 6 | 8 | |
| Hyperdiploidy | 9 | 5 | |
| TEL-AML1 | 5 | 3 | |
| Normal | 40 | 48 | |
| Others | 3 | 3 | |
| NT | 7 | 6 | |
| Relapse | 29 | 59 | < .001 |
| Death | 36 | 59 | .001 |
| Feature . | Nonmethylated,no. patients . | Methylated,no. patients . | P . |
|---|---|---|---|
| Total | 100 | 161 | |
| Age | NS | ||
| Younger than 15 y | 43 | 57 | |
| Older than 15 y | 35 | 65 | |
| Sex (M/F) | 60/40 | 61/39 | NS |
| WBC count | NS | ||
| Less than 50 × 109/L | 75 | 70 | |
| More than 50 × 109/L | 25 | 30 | |
| FAB classification | NS | ||
| L1 | 39 | 32 | |
| L2 | 49 | 57 | |
| L3 | 12 | 11 | |
| Blast lineage | NS | ||
| B cell | 91 | 89 | |
| T cell | 9 | 11 | |
| NCI risk groups | NS | ||
| Standard | 79 | 66 | |
| Poor | 21 | 34 | |
| PETHEMA risk groups | NS | ||
| Standard | 41 | 34 | |
| Poor | 59 | 66 | |
| Treatment | NS | ||
| PETHEMA 89 | 20 | 19 | |
| PETHEMA 93 | 80 | 81 | |
| BMT | 19 | 16 | NS |
| Best response | |||
| CR | 87 | 93 | NS |
| Cytogenetic/molecular abnormalities | NS | ||
| BCR-ABL | 17 | 14 | |
| t(1;19) | 4 | 2 | |
| 11q23 | 3 | 3 | |
| c-myc | 6 | 8 | |
| 7q35-14q11 | 6 | 8 | |
| Hyperdiploidy | 9 | 5 | |
| TEL-AML1 | 5 | 3 | |
| Normal | 40 | 48 | |
| Others | 3 | 3 | |
| NT | 7 | 6 | |
| Relapse | 29 | 59 | < .001 |
| Death | 36 | 59 | .001 |
Data are expressed as percentages of patient population, except where otherwise noted.
NS indicates not significant; WBC, white blood cell; FAB, French-American-British; BMT, bone marrow transplantation; NT, not tested.